Xeris Biopharma (NASDAQ:XERS) Insider Sells $120,300.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.02, for a total value of $120,300.00. Following the sale, the insider directly owned 1,676,126 shares in the company, valued at approximately $13,442,530.52. The trade was a 0.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $7.36 on Friday. The company has a market capitalization of $1.27 billion, a PE ratio of 122.67 and a beta of 0.66. The company has a 50-day simple moving average of $7.64 and a two-hundred day simple moving average of $6.79. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its stake in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after acquiring an additional 3,594 shares during the last quarter. Millennium Management LLC grew its stake in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after acquiring an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new position in shares of Xeris Biopharma during the first quarter valued at about $170,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.